Advances in pharmacotherapy for angiosarcoma

Angiosarcoma (AS) is a rare soft tissue sarcoma originating from vascular or lymphatic endothelial cells, accounting for less than 1% of soft tissue sarcomas. It is most common in skin and surface of soft tissue. The diagnosis of AS is based on pathology, and the expression of CD31, ERG and CD34 is commonly positive in immuno-histochemistry. Staging is performed according to the American Joint Committee on Cancer (AJCC)criteria for soft tissue sarcoma. Radical surgery is the primary therapy for locally confined disease. For un-resectable or metastatic angiosarcoma, chemotherapy is the main treatment method. Targeted therapy and immunotherapy have developed rapidly in recent years, and the combined therapy of different types of chemotherapy drug has been the focus of optimization in the future.